Today: 29 April 2026
Browse Category

NASDAQ:OLMA 18 November 2025 - 29 January 2026

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals shares rose 5.8% to $25.99 Thursday afternoon, adding about $127 million in market value as broader indexes fell. Trading volume reached 926,000 shares. No new company news emerged, but traders are watching for Olema’s March update and progress on its late-stage palazestrant trial. The company reported over $500 million in cash and equivalents as of Dec. 31, 2025.
29 January 2026
··
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

Olema Pharmaceuticals shares jumped 9.8% to $28.08 Friday, with 2.5 million shares traded ahead of the CEO’s Jan. 13 presentation at the J.P. Morgan Healthcare Conference. Citi, UBS, and Piper Sandler issued bullish ratings and price targets up to $60, citing upcoming trial data and potential catalysts. Olema raised $218.5 million in November. The company has no approved products and is advancing two breast cancer drug candidates.
11 January 2026
·
Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open

Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open

Olema Pharmaceuticals shares closed at $26.23 Friday, down 4.44%, capping a roughly 28% drop from mid-December highs. Year-to-date, the stock remains up about 350%. No new company news or filings appeared in the past 48 hours. Recent insider Form 4 filings show large option exercises and share sales by Director Ian T. Clark and Chief Medical Officer Naseem Zojwalla.
28 December 2025
··
Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

Olema Pharmaceuticals shares closed at $26.23 Friday, down $1.25, with about 828,000 shares traded in a thin, year-end session. The stock remains up 467.75% over the past six months. No major company news was released in the past 48 hours. Investors are watching recent insider filings and awaiting updates on Olema’s late-stage breast cancer program.
28 December 2025
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (OLMA) fell 6.2% to $28.89 intraday Friday on Nasdaq, after opening at $31.22 and swinging between $31.95 and $28.89. No new company news was released; the move follows heightened volatility since Roche’s positive Phase 3 SERD data in November and Olema’s $190 million public offering.
19 December 2025
···
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (NASDAQ: OLMA) surged over 11% to $29.68 on December 10, 2025, hitting a new 52-week high amid heavy trading. The rally followed positive Phase 3 data from Roche’s breast cancer drug trial, which boosted confidence in Olema’s own SERD candidate. Year-to-date, OLMA shares have climbed over 400%, with market cap reaching $2.37 billion.
10 December 2025
·
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.
9 December 2025
··
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····

Stock Market Today

  • Bill Ackman Launches $5 Billion Pershing Square IPO, Stays Bullish on Tech Stocks
    April 29, 2026, 12:31 PM EDT. Bill Ackman leads the dual IPO of Pershing Square Inc. and Pershing Square USA, raising $5 billion, supported by 85% institutional investors. The Pershing Square USA fund debuted at $50 on the NYSE. Ackman aims to build a diversified holding company through a $900 million stake in Howard Hughes Holdings, echoing Warren Buffett's Berkshire Hathaway model. The IPO includes a private placement securing $2.8 billion from family offices and pension funds. Ackman's portfolio continues to back the American consumer with bets on Restaurant Brands, Hilton (HLT), Alphabet (GOOGL), and Meta (META). Despite reports of OpenAI missing financial targets, he remains bullish on tech. Ackman also embraced a political shift, backing Trump due to deregulation and economic policies.

Latest article

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

29 April 2026
Mastercard shares climbed 3.8% to $526.90 Wednesday after Visa beat profit estimates and raised its outlook, sending Visa shares up 8.7%. Mastercard reports first-quarter results Thursday. The company expanded its Start Path program this week to focus on business payments, with fintech Glass joining to work on public-sector procurement. Mastercard does not lend or issue cards, earning mainly from transaction fees.
GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

29 April 2026
GE HealthCare cut its 2026 profit forecast Wednesday, citing higher chip, oil, and freight costs, as well as tariffs and a supplier issue. Shares fell nearly 13% to $59.75. First-quarter revenue rose 7.4% to $5.13 billion, but net income dropped to $389 million from $564 million a year earlier. The company also announced a reorganization, merging its Imaging and Advanced Visualization units.
Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

29 April 2026
The U.S. Commerce Department ordered Applied Materials, Lam Research, and KLA to halt some chip-tool shipments to China’s Hua Hong, Reuters reported. The move targets shipments linked to facilities believed capable of advanced chip production. Applied reported $2.10 billion in China revenue last quarter, or 30% of its total. Shares in Applied, Lam, and KLA traded lower after the news.
Go toTop